NDAORALTABLETPriority Review
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOCABRIA (cabotegravir sodium) is an oral small-molecule integrase strand transfer inhibitor approved in January 2021 for HIV infection treatment. It represents a novel class within HIV antivirals and is part of GSK's ViiV Healthcare HIV portfolio. The drug is currently in its peak commercial phase with approximately 4.8 years of patent protection remaining.
Peak4.8 years to LOE
Product is in peak commercial phase with 55 linked career opportunities, primarily across ViiV Healthcare's commercial, government affairs, and engineering teams, indicating stable-to-growing team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VOCABRIA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.